Oesophageal involvement in scleroderma

Clinical and Experimental Rheumatology

Volumn 27, Issue 3 SUPPL. 54, 2009, Pages

  Süto, Gabor ^a   Czirják, László ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Gastrointestinal tract; Oesophageal reflux disease; Oesophagus; Outcome measure; Scleroderma

Indexed keywords

DOMPERIDONE; ERYTHROMYCIN; LANSOPRAZOLE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

BARIUM MEAL; BARRETT ESOPHAGUS; DYSPHAGIA; EDITORIAL; ESOPHAGOSCOPY; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MOTILITY; ESOPHAGUS SCINTISCANNING; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LIFESTYLE MODIFICATION; MANOMETRY; MORTALITY; ODYNOPHAGIA; PH MEASUREMENT; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; QUESTIONNAIRE; REFLUX ESOPHAGITIS; SELF REPORT; STOMACH ACID SECRETION; SYSTEMIC SCLEROSIS;

ESOPHAGEAL DISEASES; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 70350325640     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. WALKER UA, TYNDALL A, CZIRJÁK L et al.: Geographic variation of disease manifestations in systemic sclerosis - report from the EULAR Scleroderma trials and reserach (EUSTAR) group database. Ann Rheum Dis published online 22 Jul 2008; doi:10.1136/ard.2008.091348
2. HUDSON M, TAILLEFER S, STEELE R et al.: Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007; 25: 754-757
3. MORITA Y, MURO Y, SUGIURA K et al.: Results of the health assessment quetionnaire for Japanese patients with systemic sclerosis - measuring functional impairment in systemic sclerosis versus other connective tissue diseases. Clin Exp Rheumatol 2007; 25: 367-372
4. VALENTINI G, MATUCCI CERINIC M: Disease-specific indicators, guidelines and outcoma measures in scleroderma. Clin Exp Rheumatol 2007; 25 (Suppl. 47): S159-S162.
5. KARASSA FB, IOANNIDIS JPA: Mortality in systemic sclerosis. Clin Exp Rheumatol 2008; 26 (Suppl. 51): S85-S93.
6. KHANNA D, HAYS RD, PARK GS et al.: Development of a Preliminary Scleroderma Gastrointestinal Tract 1.0 Quality of Life Instrument. Arthritis Rheum 2007; 57: 1280-1286
7. WALKER UA, TYNDALL A, CZIRJÁK L et al.: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma trials and reserach group database. Ann Rheum Dis 2007; 66: 754-763
8. MANETTI M, NEUMANN E, MILIA AF et al.: Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients. Arthritis Rheum 2007; 56: 3442-3447
9. BERTINOTTI L, BRACCI S, NACCI F et al.: The autonomic nervous system in systemic sclerosis. A review. Clin Rheumatol 2003; 23: 1-5.
10. DOMSIC R, FASANELLA K, BIELEFELDT K: Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 2008; 53: 1163-1174
11. EBERT EC: Gastric and entric involvement in progressive systemic sclerosis. J Clin Gastroenterol 2008; 42: 5-12.
12. LOCK G, HOLSTEGE A, LANG B, SCHOLMERICH J: Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997; 92: 763-771 (Pubitemid 27200787)
13. SALLAM H, MCNEAREY TA, CHEN JDZ: Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006; 23: 691-712.
14. MAINIE I, TUTUIAN R, PATEL A, CASTELL DO: Regional oesophageal dysfunction in scleroderma and achalasia using multichannel intraluminal impedance and manometry. Dig Dis Sci 2008; 53: 210-216
15. NTOUMAZIOS SK, VOULGARI PV, POTSIS K, KOUTIS E, TSIFETAKI N, ASSIMAKOUPILOS D: Oesophageal involvement in scleroderma: Gastrooesophageal reflux, the common problem. Semin Arthritis Rheum 2006; 36: 173-181
16. SRIDHAR KR, LANGE RC, MAGYAR L, SOYKAN I, MCCALLUM RW: Prevalence of impaired gastric emptying of solids in systemic sclerosis: Diagnostic and therpaeutic implications. J Lab Clin Med 1998; 132: 541-546
17. MARIE I, DOMINIQUE S, LEVESQUE H et al.: Oesophageal involvement on pulmonary manifestations in systemic sclerosis. Arth Care Res 2001; 45: 346-354
18. MARIE I, DUCROTTE P, DENIS P, HELLOT MF, LEVESQUE H: Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1593-601.
19. CLEMENTS PJ, BECVAR R, DROSOS AA, GHATTAS L, GABRIELLI A: Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2001; 21 (Suppl. 29.): S15-S18.
20. American gastroenterological association medical position statement on the management of gastrooesophageal reflux disease. Gastroenterology 2008; 135: 1383-1391
21. KOWAL-BIELECKA O, LANDEWÉ R, AVOUAC J et al.: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis published online 19 Jan 2009, doi:10.1136/ard.2008.096677
22. SANGER GJ, ALPERS DH: Development of drugs for gastrointestinal motor disorders: transalting science to clinical need. Neurogastroenterol Motil 2008; 20: 177-184
23. BASSOTTI G, BATTAGLIA E, DEBERNARDI V et al.: Oesophageal dysfunction in scleroderma. Relationship with disease subsets. Arthritis Rheum 1997; 40: 2252-2259